Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model

Journal of Virology

Volumn 88, Issue 11, 2014, Pages 6368-6379

  Cox, Reagan G ^a   Erickson, John J ^a   Hastings, Andrew K ^a   Becker, Jennifer C ^a   Johnson, Monika ^a   Craven, Ryan E ^a   Tollefson, Sharon J ^a   Boyd, Kelli L ^a   Williams, John V ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS FUSION PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; KIDNEY EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS TITRATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; HEK293 CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; LUNG; METAPNEUMOVIRUS; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; POLOXALENE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84899863257     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00332-14     Document Type: Article

References (77)

1. Peiris JS, Tang WH, Chan KH, Khong PL, Guan Y, Lau YL, Chiu SS. 2003. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg. Infect. Dis. 9:628-633. http://dx. doi. org/10. 3201/eid0906. 030009.
2. Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Hara M, Takahashi Y, Kobayashi K. 2004. Human metapneumovirus infection in Japanese children. J. Clin. Microbiol. 42:126-132. http://dx. doi. org/10. 1128/JCM. 42. 1. 126-132. 2004.
3. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, Wright PF, Crowe JE, Jr. 2004. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N. Engl. J. Med. 350:443-450. http://dx. doi. org/10. 1056/NEJMoa025472.
4. Sloots TP, Mackay IM, Bialasiewicz S, Jacob KC, McQueen E, Harnett GB, Siebert DJ, Masters BI, Young PR, Nissen MD. 2006. Human metapneumovirus, Australia, 2001-2004. Emerg. Infect. Dis. 12:1263-1266. http://dx. doi. org/10. 3201/eid1708. 051239.
5. Williams JV, Wang CK, Yang CF, Tollefson SJ, House FS, Heck JM, Chu M, Brown JB, Lintao LD, Quinto JD, Chu D, Spaete RR, Edwards KM, Wright PF, Crowe JE, Jr. 2006. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J. Infect. Dis. 193:387-395. http://dx. doi. org/10. 1086/499274.
6. Walsh EE, Peterson DR, Falsey AR. 2008. Human metapneumovirus infections in adults: another piece of the puzzle. Arch. Intern. Med. 168: 2489-2496. http://dx. doi. org/10. 1001/archinte. 168. 22. 2489.
7. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. 2012. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J. Infect. Dis. 206: 56-62. http://dx. doi. org/10. 1093/infdis/jis309.
8. Esper F, Martinello RA, Boucher D, Weibel C, Ferguson D, Landry ML, Kahn JS. 2004. A 1-year experience with human metapneumovirus in children aged <5 years. J. Infect. Dis. 189:1388-1396. http://dx. doi. org/10. 1086/382482.
9. Papenburg J, Hamelin ME, Ouhoummane N, Carbonneau J, Ouakki M, Raymond F, Robitaille L, Corbeil J, Caouette G, Frenette L, De Serres G, Boivin G. 2012. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J. Infect. Dis. 206:178-189. http://dx. doi. org/10. 1093/infdis/jis333.
10. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM, Crowe JE, Jr. 2005. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J. Infect. Dis. 192:1061-1065. http://dx. doi. org/10. 1086/432732.
11. Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, Fredricks DN, Corey L. 2006. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann. Intern. Med. 144:344-349. http://dx. doi. org/10. 7326/0003-4819-144-5-200603070-00010.
12. Shahda S, Carlos WG, Kiel PJ, Khan BA, Hage CA. 2011. The human metapneumovirus: a case series and review of the literature. Transpl. Infect. Dis. 13:324-328. http://dx. doi. org/10. 1111/j. 1399-3062. 2010. 00575. x.
13. Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, Collins PL, Buchholz UJ. 2004. Recombinant human metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J. Virol. 78:12877-12887. http://dx. doi. org/10. 1128/JVI. 78. 23. 12877-12887. 2004.
14. Tang RS, Mahmood K, Macphail M, Guzzetta JM, Haller AA, Liu H, Kaur J, Lawlor HA, Stillman EA, Schickli JH, Fouchier RA, Osterhaus AD, Spaete RR. 2005. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 23:1657-1667. http://dx. doi. org/10. 1016/j. vaccine. 2004. 10. 009.
15. Buchholz UJ, Nagashima K, Murphy BR, Collins PL. 2006. Live vaccines for human metapneumovirus designed by reverse genetics. Expert Rev. Vaccines 5:695-706. http://dx. doi. org/10. 1586/14760584. 5. 5. 695.
16. Herfst S, de Graaf M, Schrauwen EJ, Sprong L, Hussain K, van den Hoogen BG, Osterhaus AD, Fouchier RA. 2008. Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters. J. Gen. Virol. 89:1553-1562. http://dx. doi. org/10. 1099/vir. 0. 2008/002022-0.
17. Herfst S, Fouchier RA. 2008. Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J. Clin. Virol. 41:49-52. http://dx. doi. org/10. 1016/j. jcv. 2007. 10. 022.
18. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. 2010. New insights for development of a safe and protective RSV vaccine. Hum. Vaccin. 6:482-492. http://dx. doi. org/10. 4161/hv. 6. 6. 11562.
19. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162: 80-99. http://dx. doi. org/10. 1016/j. virusres. 2011. 09. 020.
20. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. 2013. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31(Suppl 2):B209-B215. http://dx. doi. org/10. 1016/j. vaccine. 2012. 11. 106.
21. Schickli JH, Dubovsky F, Tang RS. 2009. Challenges in developing a pediatric RSV vaccine. Hum. Vaccin. 5:582-591.
22. Ramilo O. 2009. Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. Paediatr. Respir. Rev. 10(Suppl 1):23-25. http://dx. doi. org/10. 1016/S1526-0542(09)70011-9.
23. Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe JE, Jr, Williams JV. 2007. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J. Virol. 81:698-707. http://dx. doi. org/10. 1128/JVI. 00844-06.
24. Herfst S, de Graaf M, Schrauwen EJ, Ulbrandt ND, Barnes AS, Senthil K, Osterhaus AD, Fouchier RA, van den Hoogen BG. 2007. Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J. Gen. Virol. 88:2702-2709. http://dx. doi. org/10. 1099/vir. 0. 83084-0.
25. de Swart RL, van den Hoogen BG, Kuiken T, Herfst S, van Amerongen G, Yuksel S, Sprong L, Osterhaus AD. 2007. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 25:8518-8528. http://dx. doi. org/10. 1016/j. vaccine. 2007. 10. 022.
26. Yim KC, Cragin RP, Boukhvalova MS, Blanco JC, Hamlin ME, Boivin G, Porter DD, Prince GA. 2007. Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 25:5034-5040. http://dx. doi. org/10. 1016/j. vaccine. 2007. 04. 075.
27. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
28. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:435-448.
29. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
30. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
31. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24:197-202.
32. Murphy BR, Walsh EE. 1988. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26:1595-1597.
33. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR. 1999. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J. Virol. 73:2956-2962.
34. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA. 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196:859-865. http://dx. doi. org/10. 1084/jem. 20020781.
35. Delgado MF, Polack FP. 2004. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease. Expert Rev. Vaccines 3:693-700. http://dx. doi. org/10. 1586/14760584. 3. 6. 693.
36. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41. http://dx. doi. org/10. 1038/nm. 1894.
37. Schneider-Ohrum K, Ross TM. 2012. Virus-like particles for antigen delivery at mucosal surfaces. Curr. Top. Microbiol. Immunol. 354:53-73. http://dx. doi. org/10. 1007/82_2011_135.
38. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chene I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. 2011. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3:94ra71. http://dx. doi. org/10. 1126/scitranslmed. 3002330.
39. Haynes JR. 2009. Influenza virus-like particle vaccines. Expert Rev. Vaccines 8:435-445. http://dx. doi. org/10. 1586/erv. 09. 8.
40. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. 2009. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol. 333:269-289. http://dx. doi. org/10. 1007/978-3-540-92165-3_14.
41. Young KR, McBurney SP, Karkhanis LU, Ross TM. 2006. Virus-like particles: designing an effective AIDS vaccine. Methods 40:98-117. http://dx. doi. org/10. 1016/j. ymeth. 2006. 05. 024.
42. Hendrickx G, Vorsters A, Van Damme P. 2012. Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery. Curr. Opin. Infect. Dis. 25:578-583. http://dx. doi. org/10. 1097/QCO. 0b013e328357e65c.
43. Schiller JT, Castellsague X, Villa LL, Hildesheim A. 2008. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl 10):K53-K61. http://dx. doi. org/10. 1016/j. vaccine. 2008. 06. 002.
44. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. 2005. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J. Virol. 79:12608-12613. http://dx. doi. org/10. 1128/JVI. 79. 19. 12608-12613. 2005.
45. Williams JV, Chen Z, Cseke G, Wright DW, Keefer CJ, Tollefson SJ, Hessell A, Podsiad A, Shepherd BE, Sanna PP, Burton DR, Crowe JE, Jr, Williamson RA. 2007. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J. Virol. 81:8315-8324. http://dx. doi. org/10. 1128/JVI. 00106-07.
46. Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, Donacki NE, Folliot K, Barnes AS, Senthil K, Wilson S, Chen M, Clarke L, MacPhail M, Li J, Woods RM, Coelingh K, Reed JL, McCarthy MP, Pfarr DS, Osterhaus AD, Fouchier RA, Kiener PA, Suzich JA. 2006. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J. Virol. 80:7799-7806. http://dx. doi. org/10. 1128/JVI. 00318-06.
47. Mok H, Tollefson SJ, Podsiad AB, Shepherd BE, Polosukhin VV, Johnston RE, Williams JV, Crowe JE, Jr. 2008. An alphavirus repliconbased human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. J. Virol. 82:11410-11418. http://dx. doi. org/10. 1128/JVI. 01688-08.
48. Skiadopoulos MH, Biacchesi S, Buchholz UJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR. 2006. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology. 345:492-501. http://dx. doi. org/10. 1016/j. virol. 2005. 10. 016.
49. Ryder AB, Tollefson SJ, Podsiad AB, Johnson JE, Williams JV. 2010. Soluble recombinant human metapneumovirus G protein is immunogenic but not protective. Vaccine 28:4145-4152. http://dx. doi. org/10. 1016/j. vaccine. 2010. 04. 007.
50. Cox RG, Livesay SB, Johnson M, Ohi MD, Williams JV. 2012. The human metapneumovirus fusion protein mediates entry via an interaction with RGD-binding integrins. J. Virol. 86:12148-12160. http://dx. doi. org/10. 1128/JVI. 01133-12.
51. Williams JV, Tollefson SJ, Johnson JE, Crowe JE, Jr. 2005. The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. J. Virol. 79:10944-10951. http://dx. doi. org/10. 1128/JVI. 79. 17. 10944-10951. 2005.
52. Ohi M, Li Y, Cheng Y, Walz T. 2004. Negative staining and image classification-powerful tools in modern electron microscopy. Biol. Proced. Online 6:23-34. http://dx. doi. org/10. 1251/bpo70.
53. Cerundolo V, Silk JD, Masri SH, Salio M. 2009. Harnessing invariant NKTcells in vaccination strategies. Nat. Rev. Immunol. 9:28-38. http://dx. doi. org/10. 1038/nri2451.
54. Gilchuk P, Spencer CT, Conant SB, Hill T, Gray JJ, Niu X, Zheng M, Erickson JJ, Boyd KL, McAfee KJ, Oseroff C, Hadrup SR, Bennink JR, Hildebrand W, Edwards KM, Crowe JE, Jr, Williams JV, Buus S, Sette A, Schumacher TN, Link AJ, Joyce S. 2013. Discovering naturally processed antigenic determinants that confer protective T cell immunity. J. Clin. Invest. 123:1976-1987. http://dx. doi. org/10. 1172/JCI67388.
55. + T cells through PD-1. J. Clin. Invest. 122:2967-2982. http://dx. doi. org/10. 1172/JCI62860.
56. Harrison MS, Sakaguchi T, Schmitt AP. 2010. Paramyxovirus assembly and budding: building particles that transmit infections. Int. J. Biochem. Cell Biol. 42:1416-1429. http://dx. doi. org/10. 1016/j. biocel. 2010. 04. 005.
57. Wen X, Krause JC, Leser GP, Cox RG, Lamb RA, Williams JV, Crowe JE, Jr, Jardetzky TS. 2012. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat. Struct. Mol. Biol. 19:461-463. http://dx. doi. org/10. 1038/nsmb. 2250.
58. Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindle RW. 2006. Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J. Virol. 80:2034-2044. http://dx. doi. org/10. 1128/JVI. 80. 4. 2034-2044. 2006.
59. + T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J. Virol. 86:13016-13024. http://dx. doi. org/10. 1128/JVI. 01770-12.
60. Melendi GA, Zavala F, Buchholz UJ, Boivin G, Collins PL, Kleeberger SR, Polack FP. 2007. Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus. J. Virol. 81:11461-11467. http://dx. doi. org/10. 1128/JVI. 02423-06.
61. Okamoto M, Sugawara K, Takashita E, Muraki Y, Hongo S, Nishimura H, Matsuzaki Y. 2010. Longitudinal course of human metapneumovirus antibody titers and reinfection in healthy adults. J. Med. Virol. 82:2092-2096. http://dx. doi. org/10. 1002/jmv. 21920.
62. Falsey AR, Hennessey PA, Formica MA, Criddle MM, Biear JM, Walsh EE. 2010. Humoral immunity to human metapneumovirus infection in adults. Vaccine 28:1477-1480. http://dx. doi. org/10. 1016/j. vaccine. 2009. 11. 063.
63. Hamelin ME, Couture C, Sackett M, Kiener P, Suzich J, Ulbrandt N, Boivin G. 2008. The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways [sic] hyperresponsiveness in mice. Antivir. Ther. 13:39-46.
64. Madhi SA, Ludewick H, Kuwanda L, van Niekerk N, Cutland C, Klugman KP. 2007. Seasonality, incidence, and repeat human metapneumovirus lower respiratory tract infections in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediatr. Infect. Dis. J. 26:693-699. http://dx. doi. org/10. 1097/INF. 0b013e3180621192.
65. Kolli D, Bataki EL, Spetch L, Guerrero-Plata A, Jewell AM, Piedra PA, Milligan GN, Garofalo RP, Casola A. 2008. T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection. J. Virol. 82:8560-8569. http://dx. doi. org/10. 1128/JVI. 00699-08.
66. Feuillet F, Lina B, Rosa-Calatrava M, Boivin G. 2012. Ten years of human metapneumovirus research. J. Clin. Virol. 53:97-105. http://dx. doi. org/10. 1016/j. jcv. 2011. 10. 002.
67. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. 2013. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc. Natl. Acad. Sci. USA. 110:11133-11138. http://dx. doi. org/10. 1073/pnas. 1309070110.
68. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. http://dx. doi. org/10. 1126/science. 1243283.
69. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85:7788-7796. http://dx. doi. org/10. 1128/JVI. 00555-11.
70. Delamarre L, Holcombe H, Mellman I. 2003. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J. Exp. Med. 198:111-122. http://dx. doi. org/10. 1084/jem. 20021542.
71. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. 2003. ER-phagosome fusion defines an MHC class I crosspresentation compartment in dendritic cells. Nature 425:397-402. http://dx. doi. org/10. 1038/nature01911.
72. Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK. 2011. Protein delivery using engineered virus-like particles. Proc. Natl. Acad. Sci. USA. 108:16998-17003. http://dx. doi. org/10. 1073/pnas. 1101874108.
73. Win SJ, Ward VK, Dunbar PR, Young SL, Baird MA. 2011. Crosspresentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol. Cell Biol. 89:681-688. http://dx. doi. org/10. 1038/icb. 2010. 161.
74. Leclerc D, Beauseigle D, Denis J, Morin H, Pare C, Lamarre A, Lapointe R. 2007. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J. Virol. 81:1319-1326. http://dx. doi. org/10. 1128/JVI. 01720-06.
75. Lacasse P, Denis J, Lapointe R, Leclerc D, Lamarre A. 2008. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J. Virol. 82:785-794. http://dx. doi. org/10. 1128/JVI. 01811-07.
76. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. 2002. Crosspresentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur. J. Immunol. 32:818-825. http://dx. doi. org/10. 1002/1521-4141(200203)32:3<818::AID-IMMU818>3. 0. CO;2-U.
77. Herd KA, Nissen MD, Hopkins PM, Sloots TP, Tindle RW. 2008. Major histocompatibility complex class I cytotoxic T lymphocyte immunity to human metapneumovirus (hMPV) in individuals with previous hMPV infection and respiratory disease. J. Infect. Dis. 197:584-592. http://dx. doi. org/10. 1086/526536.